+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL inhibition in bone metastases

RANKL inhibition in bone metastases

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(1): 22-26

(PDF emailed within 0-6 h: $19.90)

Accession: 055333178

Download citation: RISBibTeXText

PMID: 23302944

DOI: 10.1254/fpj.141.22

Related references

RANKL inhibition in the treatment of bone metastases. Current Opinion in Supportive and Palliative Care 2(3): 197-203, 2008

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68(8): 820-829, 2008

Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas Urologicas Espanolas 37(5): 292-304, 2014

RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opinion on Biological Therapy 9(4): 465-479, 2010

RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. Journal of Thoracic Oncology 9(3): 345-354, 2014

Discovery of osteoclast differentiation factor, RANKL Inhibition of bone resorption by blocking RANKL-RANK signaling. Japanese Journal of Pharmacology 88(Supplement 1): 17P, 2002

Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases. Prostate 73(2): 162-168, 2013

Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. Biomarkers 18(2): 121-125, 2013

Regulation of RANKL might reduce bone metastases. Lancet. Oncology 7(5): 367-367, 2006

Bone metastases in gastric cancer follow a RANKL-independent mechanism. Oncology Reports 29(4): 1453-1458, 2013

miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Molecular Cancer Research 12(1): 101-110, 2014

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. Journal of Bone and Mineral Research 23(5): 672-682, 2008

Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts. Pathology Oncology Research 18(4): 743-747, 2013

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clinical Breast Cancer 11(6): 369-375, 2012

Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases. Endocrinology 157(12): 4526-4533, 2016